[
  {
    "ts": null,
    "headline": "Here's What to Expect From Bio-Techne's Next Earnings Report",
    "summary": "Bio-Techne will release its second-quarter earnings soon, and analysts anticipate a single-digit profit dip.",
    "url": "https://finnhub.io/api/news?id=c9810470de5ab524c1f2d5c133109dbe547a13ae3ec8ca305315e4964f9d4538",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767965876,
      "headline": "Here's What to Expect From Bio-Techne's Next Earnings Report",
      "id": 138052974,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TECH",
      "source": "Yahoo",
      "summary": "Bio-Techne will release its second-quarter earnings soon, and analysts anticipate a single-digit profit dip.",
      "url": "https://finnhub.io/api/news?id=c9810470de5ab524c1f2d5c133109dbe547a13ae3ec8ca305315e4964f9d4538"
    }
  },
  {
    "ts": null,
    "headline": "A Look At Bio-Techne (TECH) Valuation After Analyst Downgrade And Softer Cash Flow Concerns",
    "summary": "Bio-Techne (TECH) is back in focus after a recent analyst downgrade that cited softer organic growth and a weaker free cash flow margin, raising fresh questions about how investors should think about the stock today. See our latest analysis for Bio-Techne. Despite the downgrade, Bio-Techne’s share price has held up reasonably well, with a 7 day share price return of 9.8% and a 90 day share price return of 10.1%. However, the 1 year total shareholder return of a 13.6% decline signals that...",
    "url": "https://finnhub.io/api/news?id=91d189018c1e81d49a06cb9f40c31f76f3509803ce67c5b5cdf5a236cf72b156",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767960643,
      "headline": "A Look At Bio-Techne (TECH) Valuation After Analyst Downgrade And Softer Cash Flow Concerns",
      "id": 138045756,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TECH",
      "source": "Yahoo",
      "summary": "Bio-Techne (TECH) is back in focus after a recent analyst downgrade that cited softer organic growth and a weaker free cash flow margin, raising fresh questions about how investors should think about the stock today. See our latest analysis for Bio-Techne. Despite the downgrade, Bio-Techne’s share price has held up reasonably well, with a 7 day share price return of 9.8% and a 90 day share price return of 10.1%. However, the 1 year total shareholder return of a 13.6% decline signals that...",
      "url": "https://finnhub.io/api/news?id=91d189018c1e81d49a06cb9f40c31f76f3509803ce67c5b5cdf5a236cf72b156"
    }
  }
]